In cancers including HCC, release of complement mediators such as C2 and C3 has been linked to macrophage polarisation and TIL functional reprogramming, raising questions as to their potential role as a therapeutic target for cancer immunotherapy.36 This evidence concerns the gene C2 and hepatocellular carcinoma.